Abstract
There were conduced researches of efficiency and safety of application of the antagonist of glutamate NMDA-receptors at patients in the acute period of a stroke. As a medical therapy has been chosen PK-Mertz. Against the background of treatment in the main group it was noted reduction of neurologic deficiency on a scale NIHSS for 39.1% (р<0.005). At the same time the good effect was observed at patients with a slight stroke (assessment on NIHSS<7). It doesn’t depend on age and subtype of ischemic stroke.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
